Male periconceptional ribavirin-interferon alpha-2B exposure with no adverse fetal effects

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 67, Issue 1, 2003, Pages 77-78

  Bianca, Sebastiano ^a,b   Ettore, Giuseppe ^c  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c Azienda Ospedaliera Garibaldi   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

REBETRON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; ALPHA2B INTERFERON; ANTIVIRUS AGENT;

CHRONIC HEPATITIS; DRUG EFFECT; ENVIRONMENTAL EXPOSURE; FETOTOXICITY; FETUS MALFORMATION; FETUS RISK; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; MUTAGENICITY; NONHUMAN; PREGNANCY COMPLICATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; TERATOGENICITY; CASE REPORT; DRUG COMBINATION; FEMALE; MALE; PREGNANCY; PREGNANCY OUTCOME;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; PATERNAL EXPOSURE; PREGNANCY; PREGNANCY OUTCOME; RIBAVIRIN;

EID: 0038132954     PISSN: 15420752     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdra.10105     Document Type: Letter

References (15)

1. Addis A, Sharabi S, Bonati M. 2000. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf 23:245-253.
2. Anonymous. 1986. Ribavirin aerosol approved for severe cases of RSV in infants and young children. FDA Drug Bull 16:7.
3. Atmar RL, Englund JA, Hammill H. 1992. Complications of measles during pregnancy. Clin Infect Dis 14:217-226.
4. Bortolussi RA, Gold R. 1988. Ribavirin aerosol therapy: safety for staff. CMAJ 138:204.
5. Collins TFX. 1978. Reproduction and teratology guidelines: review of deliberations by the National Toxicology Advisory Committee's reproduction panel. J Environ Pathol Toxicol 2:141-147.
6. Ferm VH, Willhite C, Kilham L. 1978. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 17:93-102.
7. Friedman JM, Little BB, Brent RL, Cordero JF, Hanson JW, Shepard TH. 1990. Potential human teratogenicity of frequently prescribed drugs. Obstet Gynecol 75:594-599.
8. Hagenbarth K, Maurer U, Kroisel PM, Fickert P, Trauner M, Stauber RE. 2001. No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. Am J Gastoenterol 96:2286-2287.
9. Johnson EM. 1990. The effects of ribavirin on development and reproduction: a critical review of published and unpublished studies in experimental animals. J Am Coll Toxicol 9:551-561.
10. Kilham L, Ferm VH. 1977. Congenital anomalies induced in hamster embryos with ribavirin. Science 195:413-414.
11. Kochhar DM, Penner JD, Knudsen TB. 1980. Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol 52:99-112.
12. Mishkin D, Deschenes M. 2001. Conception soon after discontinuing interferon/ribavirin therapy: a succesful outcome. Am J Gastoenterol 96: 2285.
13. Narayana K, D'Souza UJ, Seetharama Rao KP. 2002. Ribavirin-induced sperm shape abnormalities in Wistar rat. Mutat Res 15:193-196.
14. Rodriguez WJ, Bui RH, Connor JD, Kim HW, Brandt CD, Parrott RH, Burch B, Mace J. 1987. Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infection. Antimicrob Agents Chemother 31:1143-1146.
15. Tanner JM, Whitehouse RH. 1976. Clinical longitudinal standards for height, weight, height velocity, weight velocity and stages of puberty. Arch Dis Child 51:170-179.